JPS608221A - Drug against athelete's foot - Google Patents
Drug against athelete's footInfo
- Publication number
- JPS608221A JPS608221A JP11647083A JP11647083A JPS608221A JP S608221 A JPS608221 A JP S608221A JP 11647083 A JP11647083 A JP 11647083A JP 11647083 A JP11647083 A JP 11647083A JP S608221 A JPS608221 A JP S608221A
- Authority
- JP
- Japan
- Prior art keywords
- foot
- athlete
- trichophyton
- aromatic halide
- main component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
【発明の詳細な説明】 本発明は水虫薬に関する。[Detailed description of the invention] The present invention relates to an athlete's foot medicine.
水虫は皮膚病の一種であって、白疵菌によって病変を生
ずるものである。この白疵菌は皮唐の角層の厚い部分、
例えば足の痕や手のひらに繁殉し易い5.ぞして足の場
合には、犀の裏の土踏ま・」゛に数個の小さな水抱がで
き、この水均が廂痘に変わるとともに、次第に故を増し
て皮1苔がただれた状態になる。この他に指の間や、あ
るいは爪をJ5がJ水虫もある。Athlete's foot is a type of skin disease, and lesions are caused by the fungus Lepidoptera. This bacterium is found in the thick part of the horny layer of the skin,
For example, it is easy to get injured on foot marks or palms.5. In the case of the feet, several small welts form on the arch of the soles of the rhinoceroses, and as these scabs turn into pox, they gradually become sore that the skin becomes moss-covered. become. In addition to this, there is also J5 athlete's foot between the fingers or on the nails.
水虫薬としては各種のものが重版されてJ3す、大部分
tよ外用薬である。従来の外用薬はいずれも試験管内で
白W菌の発育をjll +「りる作;11のある坊。Various types of athlete's foot medicines have been reprinted, and most of them are external medicines. All conventional topical medicines inhibit the growth of white W fungi in test tubes.
白疵剤である。しかるに従来のこのような外用薬によっ
ては、なかなか水虫が完治しないという欠点があった。It is a white defect agent. However, these conventional external medicines have the drawback of not completely curing athlete's foot.
これは白W菌が角層の厚い部分の中に寄生しているため
に、薬剤が浸透し難いことによるものであった。また白
痙菌の内でも薬剤に対して比較的抵抗の強いしようこう
色画や石膏杆菌による場合が多いからである。一方向服
薬としてはグリセオフルビンが知られているが、このグ
リセオフルビンによって水虫を冶魚ダる場合には、非常
に長い期間、例えば数カ月に屋っで内IKシなりればな
らないという欠点があった。This was because the white W fungus was parasitic in the thick part of the stratum corneum, making it difficult for the drug to penetrate. Furthermore, among the white spasmodic bacteria, it is often caused by gypsum and gypsum rods, which are relatively resistant to drugs. Griseofulvin is known as a one-way drug, but when treating athlete's foot with griseofulvin, it has the disadvantage that it must be administered indoors for a very long period of time, for example, several months.
本願発明者は、モノクロロベンゼン等の芳香族ハロゲン
化物が白疵菌に対して極めて優れたル°L1″A工1作
用をもたらすことを見出した。そして本発明(Jこのよ
うな知見に基づいてなされ1こものであって、芳香族ハ
ロゲン化物を用いることによって極めて短期間で完治す
るようにした水虫薬を提供することを目的とするもので
ある。The inventor of the present invention has discovered that aromatic halides such as monochlorobenzene have an extremely excellent action against white blight. Based on this knowledge, the present invention (J) The object of the present invention is to provide a medicine for athlete's foot that uses an aromatic halide to completely cure athlete's foot in a very short period of time.
以下本発明を実施例によって詳細に説明する。The present invention will be explained in detail below using examples.
本願発明者は下記のような組成に係る液状の水虫共を調
製した。The inventor of the present application prepared a liquid athlete's foot having the following composition.
98%モノクロロベンゼン 10重Φ部0.3%堪素水
10距市部
]ニタノール 10重量部
ザルデル酸く粉末) 2重量部
このJ:うな水虫薬を指の間にできたj1間白邂の患者
に外用した。なおこの患者は約5年間にhつで程間白釘
に悩まされており、各種の外用薬を使用しているが、完
治しておらず、毎年春先から秋にかけてかなりひどい病
変が足の指の間に生じてい lこ 。98% monochlorobenzene, 10 parts by weight, 0.3% pure water, 10 parts by weight, nitanol, 10 parts by weight, Zardel acid powder) 2 parts by weight. Applied externally to patients. This patient has been suffering from white nails due to hives for about 5 years, and although he has used various topical medications, he has not been completely cured, and every year from early spring to autumn, quite severe lesions appear on his toes. It is occurring between.
この愚老に対して、に記の組成に係る水虫薬を刷毛で足
の指の間に塗布した。なお」1記の薬は静置し一装置く
と2層分薗し−Cしまうのぐ、塗る前に必=J’ J:
<振って用いるにうにした。第1口重は、水根をつぶ
した部分に」−記の桑を塗布した。すると湿っていた病
変部が次第に乾いてきた。なお上記桑の塗布は1113
回行なった。そし72日目以降になると足の指の間のか
ゆみがなくなり、指の間の病変部の大ささも次第に小ざ
くなつでゆき、5日後には病変部が非常に小さくなった
。6日目以降も毎日1日3回薬を付けた結果、10日口
重はかゆみが完全になくなるとと−しに、病変部は元の
づ−べすべした皮崩に回復した。An athlete's foot medicine having the composition described below was applied to the toes between the toes using a brush. Please note that the medicine mentioned in item 1 should be left undisturbed and then divided into two layers.
<Shake it up and use it. The first step was to apply mulberry to the area where the water roots had been crushed. Then, the moist lesion gradually became dry. The above mulberry coating is 1113
I went around. After the 72nd day, the itching between the toes disappeared, and the size of the lesion between the toes gradually became smaller, and after 5 days, the lesion had become very small. After the 6th day, the medicine was applied three times a day, and on the 10th day, the itching in the mouth completely disappeared, and the affected area returned to its original smooth, flaky appearance.
このように本実施例に係る水虫薬によれば、従来の外用
薬に比較して追かに顕著な効果が得られるとともに、外
用する期間も従来の外用薬に比べて追かに短くなること
が証明された。これは上記の薬に含まれる主成分である
モノクロロベンゼンの坑白鉦作用によるものであって、
しかもこのモノクロロベンゼンが高い浸透力を有するた
めに、角層の中に寄生している自前菌をも効果的に殺り
ことができるものによるものと考えられる。As described above, according to the athlete's foot medicine according to the present example, a more remarkable effect can be obtained compared to conventional external medicines, and the period of external application is also shorter than that of conventional external medicines. has been proven. This is due to the anti-inflammatory action of monochlorobenzene, the main ingredient contained in the above medicine.
Moreover, this monochlorobenzene has a high penetrating power, so it is thought that this is because it can effectively kill the native bacteria that are parasitic in the stratum corneum.
以上本発明を実施例につき説明したが、本ブを明はこの
実施例によって限定されることなく、本発明の技術的思
想に基づいて各種の変更が可能である。例えば上記実施
例においてはモノクロロベンゼン(CH5Cj2)を主
成分として用いるようにしているが、このモノクロL」
ベンゼンに代えてしノブロロベンゼン(CHsBr)を
用いるようにしてもよい。またこれらの芳香族ハ[」グ
ン化物のハ[1ゲン元素の置換の位置はオルト、メタ、
パラのいずれの位置であってもJ:り、各種の異性体を
利用づることが可能である。Although the present invention has been described above with reference to embodiments, the present invention is not limited to these embodiments, and various modifications can be made based on the technical idea of the present invention. For example, in the above example, monochlorobenzene (CH5Cj2) is used as the main component, but this monochrome L''
Nobrolobenzene (CHsBr) may be used instead of benzene. In addition, the substitution position of the halogen element in these aromatic halides is ortho, meta,
It is possible to use various isomers of J: at any position of para.
以上に述べたJ:うに本発明は、ベンゼン環に3−1合
されている水素をハロゲン元素で置換した芳香族ハロゲ
ン化物を主成分として用いるJ:うにし/j水虫薬に関
するものである。従って本発明にJ:れば、高い坑白釘
作用が奏され、短期間で水虫を完治することができる水
虫薬を提供することがiil能どなる。The above-mentioned J: Sea urchin/J athlete's foot medicine uses as a main component an aromatic halide in which the hydrogen bonded 3-1 to the benzene ring is replaced with a halogen element. Therefore, according to the present invention, it is possible to provide a medicine for athlete's foot that has a high potency and can completely cure athlete's foot in a short period of time.
代理人 松 利 修Agent Toshi Osamu Matsu
Claims (1)
した芳香族ハロゲン化物を主成分として用いることを特
徴とする水虫薬。An athlete's foot medicine characterized by using as a main ingredient an aromatic halide in which hydrogen bonded to a benzene ring is replaced with a halogen element.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11647083A JPS608221A (en) | 1983-06-28 | 1983-06-28 | Drug against athelete's foot |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11647083A JPS608221A (en) | 1983-06-28 | 1983-06-28 | Drug against athelete's foot |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS608221A true JPS608221A (en) | 1985-01-17 |
JPH0211566B2 JPH0211566B2 (en) | 1990-03-14 |
Family
ID=14687897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP11647083A Granted JPS608221A (en) | 1983-06-28 | 1983-06-28 | Drug against athelete's foot |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS608221A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4162577B2 (en) * | 2003-11-25 | 2008-10-08 | 株式会社東芝 | Cooker and cooking utensil used for the cooker |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5115637A (en) * | 1974-07-26 | 1976-02-07 | Yukio Kobayashi | Ch3 cooh to pentakurorufuenoorunokongonyoru satsukinseibutsushitsu |
-
1983
- 1983-06-28 JP JP11647083A patent/JPS608221A/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5115637A (en) * | 1974-07-26 | 1976-02-07 | Yukio Kobayashi | Ch3 cooh to pentakurorufuenoorunokongonyoru satsukinseibutsushitsu |
Also Published As
Publication number | Publication date |
---|---|
JPH0211566B2 (en) | 1990-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LESSER | Testosterone propionate therapy in one hundred cases of angina pectoris | |
Lewis et al. | Fatal adrenal cortical insufficiency precipitated by surgery during prolonged continuous cortisone treatment | |
US3795739A (en) | Treatment of parkinson disease | |
Boland | Prednisone and prednisolone therapy in rheumatoid arthritis: Clinical evaluation based on continuous observations for periods of six to nine months | |
US4210670A (en) | Antithrombotic agents | |
JPH0637395B2 (en) | A drug for treating amyotrophic lateral sclerosis, containing a dipeptide derivative | |
Buckle | Treatment of thyroid crisis by beta-adrenergic blockade | |
Mckinney Jr et al. | Depression with the use of alpha-methyldopa | |
JPS5938203B2 (en) | A therapeutic agent for cerebral circulation disorders whose main ingredient is coenzyme Q. | |
US5331012A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
JPS608221A (en) | Drug against athelete's foot | |
Silver et al. | Chronic arsenic poisoning following use of an asthma remedy | |
US3039927A (en) | Pharmaceutical composition comprising aspirin and sorbitol | |
WO1999016432A1 (en) | A drug for treating diabetic nephrosis | |
US4006249A (en) | Systemic treatment of psoriasis | |
US4073897A (en) | Treatment of arthritis and allied conditions with xenylsalate | |
JP2002522507A (en) | Treatment of disease states | |
JPH06239757A (en) | Antiallergic agent | |
US3090724A (en) | Method of treating dermatological conditions | |
JPS58213719A (en) | Drug activator | |
JPS62123132A (en) | Composition for remedying bronchial asthma | |
McGAVACK et al. | Effect of Desoxycorticosterone Acetate on Glucose Tolerance in Normal Individuals and in Patients with Addison’s Disease | |
US2991225A (en) | Omicron-methylbenzhydryl-beta-dimethylaminoethyl ether process and composition for symptomatic relief of the syndrome of parkinsonism and of spastic skeletal muscle disorders | |
JPS6111A (en) | Remedy for demyelinating disease | |
JPS5951926B2 (en) | anticancer drug |